James Herriott - 23 Mar 2026 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Reporting relationship: SVP, General Counsel & Sec
Issuer ticker: EXAS
Reported as of: 23 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2026, 09:20:51 UTC
Prior SEC filing: 27 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ James Herriott by Mark Busch, attorney-in- fact

Key filing fact

James Herriott filed Form 4 for EXACT SCIENCES CORP (EXAS) on 23 Mar 2026.

Key facts

This page summarizes James Herriott's Form 4 filing for EXACT SCIENCES CORP (EXAS).
5 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 23 Mar 2026, 09:20.

Change

Previous filing in this sequence was filed on 27 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001957680 Primary reporting owner

Herriott James

Relationship: SVP, General Counsel & Sec
Address: C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON
Signature: /s/ James Herriott by Mark Busch, attorney-in- fact
Signature date: 23 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -68,195
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Footnotes: F1

EXAS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -1,762
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Held in 401(k) Plan
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -793
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 793
Exercise price: $92.62
Footnotes: F2, F3

EXAS transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -2,861
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,861
Exercise price: $98.18
Footnotes: F3, F4

EXAS transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -20,321
Change %: -100%
Price
Shares after: 0
Date: 23 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,321
Exercise price
Footnotes: F5, F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

James Herriott is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 7 footnotes

Footnote F1

On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

Footnote F2

These options became exercisable on February 26, 2023.

Footnote F3

At the Effective Time, each option to purchase shares of Common Stock granted under an Issuer stock plan and outstanding and unexercised as of immediately prior to the Effective Time was cancelled and, in the case of any such option the per-share exercise price of which was less than the Merger Consideration, converted into the right to receive a cash payment equal to the number of shares of Common Stock for which such option was exercisable multiplied by the excess of the Merger Consideration over the per-share exercise price of such option, less any applicable tax withholding

Footnote F4

These options became exercisable on February 14, 2024.

Footnote F5

Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

Footnote F6

These RSUs vest in four equal annual installments beginning on February 25, 2027.

Footnote F7

At the Effective Time, each outstanding RSU as of immediately prior to the Effective Time that was granted on or after November 19, 2025 was assumed by Parent at the Effective Time as a Parent restricted stock unit on substantially the same terms and conditions as were applicable to the corresponding RSU (including with respect to double-trigger vesting protections), with the number of Parent common shares underlying such Parent restricted stock unit determined based on the Merger Consideration divided by the average closing price of a Parent common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.